<table id="t2" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Significant Drug Interactions with mefenamic acid</caption>
<col align="center" valign="top" width="20%"></col>
<col align="left" valign="top" width="80%"></col>
<tbody>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Drugs That Interfere with Hemostasis</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">
<list listtype="unordered" stylecode="disc">
<item>Mefenamic acid and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of mefenamic acid and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">Monitor patients with concomitant use of  PONSTEL with anticoagulants (e.g.,warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see <content stylecode="italics">
<linkhtml href="#ht">WARNINGS; Hematologic Toxicity</linkhtml>)</content>.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Aspirin</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content stylecode="italics">(see  <linkhtml href="#Gastrointestinal">WARNINGS; Gastrointestinal Bleeding, Ulceration and Perforation</linkhtml>)</content>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">Concomitant use of PONSTEL and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see <content stylecode="italics">
<linkhtml href="#ht">WARNINGS; Hematologic Toxicity</linkhtml>).</content>
<br/>PONSTEL is not a substitute for low dose aspirin for cardiovascular protection.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">
<list listtype="unordered" stylecode="disc">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">
<list listtype="unordered" stylecode="disc">
<item>During concomitant use of PONSTEL and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
<item>During concomitant use of PONSTEL and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function <content stylecode="italics">(see <linkhtml href="#Renal">WARNINGS; Renal Toxicity and Hyperkalemia</linkhtml>).</content>
</item>
<item>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects <content stylecode="italics">(see <linkhtml href="#Renal">WARNINGS; Renal Toxicity and Hyperkalemia</linkhtml>).</content>
</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Digoxin</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">The concomitant use of mefenamic acid with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL and digoxin, monitor serum digoxin levels.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Lithium</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<content stylecode="italics">.</content> The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL and lithium, monitor patients for signs of lithium toxicity.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Methotrexate</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL and methotrexate, monitor patients for methotrexate toxicity.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Cyclosporine</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Concomitant use of PONSTEL and cyclosporine may increase cyclosporine's nephrotoxicity.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL and cyclosporine, monitor patients for signs of worsening renal function.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">NSAIDs and Salicylates</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Concomitant use of mefenamic acid with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">(see <linkhtml href="#Gastrointestinal">WARNINGS; Gastrointestinal Bleeding, Ulceration and Perforation</linkhtml>).</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">The concomitant use of mefenamic acid with other NSAIDs or salicylates is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Pemetrexed</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">Concomitant use of PONSTEL and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">During concomitant use of PONSTEL and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.<br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Antacid</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Rrule">In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the C<sub>max</sub> and AUC of mefenamic acid by 125% and 36%, respectively.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule">Concomitant use of mefenamic acid and antacids is not generally recommended because of possible increased adverse events .</td>
</tr>
</tbody>
</table>